KSB 302

Drug Profile

KSB 302

Alternative Names: CBF-BS2; KSB302

Latest Information Update: 14 Jun 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KS Biomedix Holdings
  • Class Disease-modifying antirheumatics
  • Mechanism of Action Glucose-6-phosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 14 Jun 2002 Discontinued - Phase-II for Rheumatoid arthritis in United Kingdom (PO)
  • 24 May 2001 A phase IIb trial in Europe of KSB 302 has commenced
  • 23 Aug 2000 A study in rheumatoid arthritis patients has been added to the adverse events and therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top